Your browser is no longer supported. Please, upgrade your browser.
BFRI [NASD]
Biofrontera Inc.
Index- P/E- EPS (ttm)-1.30 Insider Own69.00% Shs Outstand11.82M Perf Week-31.15%
Market Cap41.02M Forward P/E- EPS next Y-0.84 Insider Trans0.00% Shs Float3.60M Perf Month-68.54%
Income-10.40M PEG- EPS next Q-0.17 Inst Own0.10% Short Float60.10% Perf Quarter-
Sales19.00M P/S2.16 EPS this Y0.00% Inst Trans319.15% Short Ratio0.11 Perf Half Y-
Book/sh-2.17 P/B- EPS next Y66.40% ROA- Target Price15.50 Perf Year-
Cash/sh0.15 P/C22.79 EPS next 5Y- ROE- 52W Range2.25 - 14.63 Perf YTD-53.86%
Dividend- P/FCF- EPS past 5Y- ROI-166.70% 52W High-76.28% Beta-
Dividend %- Quick Ratio0.40 Sales past 5Y- Gross Margin51.20% 52W Low54.22% ATR1.39
Employees56 Current Ratio0.90 Sales Q/Q-6.50% Oper. Margin- RSI (14)36.32 Volatility13.32% 19.13%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.15 Prev Close4.00
ShortableYes LT Debt/Eq- EarningsNov 30 BMO Payout- Avg Volume19.00M Price3.47
Recom2.00 SMA20-49.31% SMA50-39.02% SMA200-36.34% Volume2,869,502 Change-13.25%
Jan-18-22 09:25AM  
Jan-13-22 08:45AM  
Jan-10-22 08:45AM  
Dec-30-21 08:45AM  
Dec-21-21 11:04AM  
07:33AM  
Dec-17-21 01:50PM  
Dec-15-21 01:46PM  
Dec-13-21 05:02PM  
09:09AM  
Dec-08-21 09:32AM  
Dec-07-21 04:23PM  
Dec-06-21 09:00AM  
Dec-02-21 12:38PM  
09:15AM  
Dec-01-21 07:05PM  
Nov-30-21 09:20AM  
Nov-29-21 09:27AM  
Nov-24-21 10:45AM  
04:56AM  
Nov-23-21 08:15AM  
Nov-16-21 09:03AM  
Nov-02-21 02:45PM  
Oct-28-21 09:40PM  
Oct-14-21 06:31AM  
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.